For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $13.01 down -2.25% from its previous closing price of $13.31. In other words, the price has decreased by -$2.25 from its previous closing price. On the day, 1.53 million shares were traded. DAWN stock price reached its highest trading level at $13.6681 during the session, while it also had its lowest trading level at $12.8631.
Ratios:
For a deeper understanding of Day One Biopharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 18 ’24 when SAMUEL BLACKMAN bought 2,206 shares for $13.21 per share.
JEREMY BENDER bought 10,554 shares of DAWN for $139,420 on Nov 18 ’24. On Nov 08 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 18,255 shares for $16.17 each. As a result, the insider received 295,229 and left with 1,067,535 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1312006528 and an Enterprise Value of 786496192. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.96 while its Price-to-Book (P/B) ratio in mrq is 2.36. Its current Enterprise Value per Revenue stands at 7.714 whereas that against EBITDA is -3.827.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $11.30. The 50-Day Moving Average of the stock is -9.65%, while the 200-Day Moving Average is calculated to be -11.16%.
Shares Statistics:
For the past three months, DAWN has traded an average of 1.05M shares per day and 1415200 over the past ten days. A total of 87.23M shares are outstanding, with a floating share count of 68.44M. Insiders hold about 32.14% of the company’s shares, while institutions hold 81.55% stake in the company. Shares short for DAWN as of 1730332800 were 18018911 with a Short Ratio of 17.19, compared to 1727654400 on 15667396. Therefore, it implies a Short% of Shares Outstanding of 18018911 and a Short% of Float of 21.59.
